Core Viewpoint - The European Commission has approved a new 7.2 mg weekly maintenance dose of Wegovy (semaglutide injection) for adult obesity patients, allowing EU doctors to prescribe this higher dosage for enhanced weight loss and muscle function maintenance [1] Group 1 - The approval allows for a prescription of 7.2 mg, which can be administered as three injections of 2.4 mg each, still maintaining a weekly injection schedule [1] - Novo Nordisk has submitted a marketing authorization application for the 7.2 mg single-dose injection pen in the EU, with potential approval and market launch expected this year [1] - In the EU, adult obesity patients can increase their dosage to 7.2 mg after using the 2.4 mg dose for at least four weeks to achieve greater weight loss [1] Group 2 - Wegovy 7.2 mg has already been approved and launched in the UK, while the FDA and other regulatory bodies in multiple countries are reviewing its registration applications [1]

Core Insights - The European Commission has approved a new 7.2mg weekly maintenance dose of Wegovy (semaglutide injection) for adult obesity patients, providing doctors with a new treatment option for patients needing further weight loss after using the 2.4mg dose [1] - The approval is based on a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) [1] - Wegovy 7.2mg has already been approved and launched in the UK, with applications under review by the FDA and other regulatory bodies in various countries [1] Group 1: Approval and Dosage - The new 7.2mg dose allows for a single injection of three 2.4mg doses weekly, enabling patients to achieve greater weight loss while maintaining muscle function after at least four weeks on the 2.4mg dose [1] - Novo Nordisk has submitted a marketing authorization application for the 7.2mg single-dose injection pen in the EU, with potential approval and market launch expected this year [1] Group 2: Clinical Study Results - Two clinical studies, STEP UP (1,407 participants) and STEP UP T2D (512 participants), showed that participants receiving the 7.2mg dose with lifestyle interventions lost significantly more weight than those on placebo [2] - In non-diabetic adult obesity participants, the Wegovy 7.2mg group achieved an average weight loss of 21%, compared to approximately 2% in the placebo group [3] - About one-third of participants experienced a weight reduction of 25% or more, with 84% of the weight loss attributed to fat mass reduction while preserving muscle function [3] Group 3: Side Effects and Expert Commentary - The most common adverse reactions included nausea, diarrhea, vomiting (24.8%), and abnormal sensations (22.9%), which were generally mild to moderate and transient [3] - The executive vice president of Novo Nordisk emphasized that this approval represents a significant advancement in helping the obese population achieve more substantial weight loss and offers greater flexibility for healthcare professionals in creating individualized treatment plans [3]

Core Viewpoint - The European Commission has approved a new higher dosage of Wegovy (semaglutide injection) at 7.2 mg for long-term weight management in obese adults, providing a stronger option for patients who do not achieve sufficient weight loss with the standard 2.4 mg dosage [5][10]. Summary by Sections Approval and Dosage Strategy - The approval of the 7.2 mg dosage is based on positive recommendations from the EMA and data from the STEP UP trial, indicating that this dosage is not merely an increase but offers an option for patients with lower weight loss ceilings [5]. - The 7.2 mg dosage is administered through three injections of 2.4 mg each week, maintaining the same frequency but increasing the complexity of administration [7]. Efficacy and Weight Loss Outcomes - In the STEP UP study, the average weight loss for the 7.2 mg group was 20.7%, compared to 17.5% for the 2.4 mg group and 2.4% for the placebo [7]. - The 7.2 mg dosage is positioned as an accelerator for patients aiming for more significant weight loss rather than a universal entry point for all patients [8]. Treatment Adherence and Real-World Data - When considering treatment adherence, the 7.2 mg group showed an 18.7% weight loss, while the control group had a 3.9% loss, with 90.7% of the 7.2 mg group achieving at least 5% weight loss [8]. - This data reflects real-world clinical variability, which is crucial for understanding the potential outcomes in broader public health contexts [8]. Safety and Tolerability - The primary adverse events for the 7.2 mg dosage remain gastrointestinal reactions, with a higher discontinuation rate due to these effects compared to the 2.4 mg group [9]. - Balancing stronger weight loss with sustainable medication use will depend on physicians' ability to manage patient profiles and side effects [9]. Market Implications - The approval of the 7.2 mg dosage expands Wegovy's dosage options in Europe, creating a more comprehensive treatment pathway for patients requiring significant weight loss [10]. - The structured dosage approach from initial low doses to higher maintenance doses allows for tailored treatment plans for patients who have been on the 2.4 mg dosage for at least four weeks [10].

Core Viewpoint - Novo Nordisk's GLP-1 drug Wegovy has received conditional marketing authorization from Health Canada for treating adults with moderate to severe liver fibrosis (F2-F3) associated with non-alcoholic steatohepatitis (NASH), marking its expansion into liver disease treatment beyond obesity and metabolic disorders [5]. Regulatory Perspective - The conditional approval indicates that further research is needed to validate long-term efficacy and safety, reflecting a cautious support from regulators for products with clear potential clinical benefits in the NASH field, which currently lacks established treatment options [7]. Market and Medical Value - As Wegovy's indications continue to expand, its positioning within the metabolic disease spectrum is evolving from a singular weight loss and diabetes treatment to a comprehensive therapeutic tool addressing obesity, metabolic syndrome, and related organ damage, thereby stretching its commercial and medical value boundaries in the global market [7].